EyePoint's New LUGANO Analyses Show DURAVYU Non-Inferiority Excluding Asymmetric Cohort
EYPT is trading near its 52-week low of $3.95 (11% above the low).
Summary
EyePoint released new post-hoc analyses of the LUGANO trial showing DURAVYU achieved non-inferiority when excluding a 9-patient asymmetric cohort, supporting a potential NDA filing in H1 2027 pending positive LUCIA results.
Key Events · Product Development and Regulatory · EYPT
-
New Post-Hoc Analyses Reframe LUGANO Miss
Excluding a 9-patient asymmetric cohort with vision loss from non-wet AMD causes, DURAVYU achieved nominal non-inferiority (p=0.0096) in BCVA change from baseline vs aflibercept.
-
Median and Randomization Analyses Support Non-Inferiority
Median regression showed a -1.4 letter difference vs aflibercept, and random reassignment of 16 patients with ≥15-letter vision loss resulted in DURAVYU non-inferiority in 10/10 simulations.
-
GA and Fibrosis Data Address Safety Concerns
New GA analyses showed onset of new GA was greater in the aflibercept arm (29% vs 5% at Week 56), and DURAVYU had lower fibrosis progression (+46% vs +193%).
-
NDA Filing Strategy Hinges on LUCIA Results
Company plans pre-NDA meeting in Q4 2026 and NDA submission in H1 2027, contingent on positive LUCIA topline data expected Q4 2026.
Analysis · EYPT · Industrial Applications And Services
EyePoint posted an expanded investor presentation with new post-hoc analyses of the failed LUGANO Phase 3 trial. Excluding a 9-patient asymmetric cohort with vision loss from non-wet AMD causes, DURAVYU achieved nominal non-inferiority (p=0.0096) in visual acuity. Median regression and 10/10 randomization simulations also supported non-inferiority. These analyses are the company's attempt to reframe the August 17 topline miss as a statistical artifact and build a case for FDA submission pending positive LUCIA results in Q4 2026. The new GA data showing lower fibrosis progression and similar GA growth rates addresses a key safety concern raised by the asymmetric cohort. This is a material update because it directly affects the probability of NDA filing and approval for the company's lead asset.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EYPT was trading at $4.40 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $374.2M. The 52-week trading range was $3.95 to $19.11. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.